 |
Previous Article | Next Article 
The Journal of Neuroscience, 2001, 21:RC192:1-6
RAPID COMMUNICATION
Psychostimulants Differentially Regulate Serotonin Transporter
Expression in Thalamocortical Neurons
Terri L.
Whitworth,
Laura C.
Herndon, and
Michael W.
Quick
Department of Neurobiology, University of Alabama at Birmingham,
Birmingham, Alabama 35294
 |
ABSTRACT |
5-HT transporters (SERTs) are transiently expressed in
thalamocortical neurons during development, permitting these
glutamatergic neurons to co-release 5-HT as a "borrowed"
transmitter. The high level of SERT expression in these neurons is
likely important in the serotonergic modulation of neocortical circuits
and provides a system for examining endogenous SERT regulation. We
tested the hypothesis that developmental expression of SERT in
thalamocortical neurons is regulated by psychostimulants that are
agonists and antagonists of SERT. Cultured thalamocortical neurons from
embryonic day 18 rats were examined for SERT expression until P15. In
untreated cultures, SERT protein levels peaked at postnatal day 3 (P3)
and were absent by P10. Chronic treatment with SERT substrates (5-HT, 3,4-methylenedioxymethamphetamine) increased both peak SERT
protein levels (fourfold) and the time course of SERT expression. SERT substrates also shifted the relative functional expression of SERT by
redistributing intracellular SERT protein to the plasma membrane. The
subcellular redistribution was prevented by PKC activators. SERT
antagonists (e.g., fluoxetine, cocaine) reduced total SERT
expression levels and the time course of SERT expression. These data
(1) show that endogenous SERT is differentially regulated by 5-HT and
psychostimulants, (2) indicate that SERT modulation occurs via changes
in both total SERT protein levels and subcellular redistribution of the
transporter, and (3) suggest that some of the actions of drugs of abuse
in neocortical development may be attributable to alterations in SERT
expression and concomitant changes in 5-HT signaling.
Key words:
cortex; development; drug abuse; monoamine; regulation; uptake
 |
INTRODUCTION |
The
cerebral cortex is innervated by serotonergic afferents during early
stages of development, suggesting that this modulatory system plays an
important role in the formation of the intricate neural circuits that
comprise the mammalian neocortex (Buznikov and Shmukler, 1981 ; Lauder,
1993 ). In rodents, 5-HT immunocytochemistry reveals dense cortical 5-HT
staining that disappears within the first several postnatal weeks
(D'Amato et al., 1987 ). Some of this innervation comes from 5-HT
neurons originating in the raphe (Bennett-Clarke et al., 1993 ).
However, the spatial and temporal pattern of 5-HT immunoreactivity
correlates directly with the expression of 5-HT transporters found on
synaptic vesicles (Lebrand et al., 1998 ) and neuronal plasma membranes
(Hansson et al., 1998 ; Lebrand et al., 1998 ) of nonserotonergic
neurons. These transporters have been localized to glutamatergic
thalamocortical afferents (Lebrand et al., 1996 ; Bruning and Liangos,
1997 ). Because the machinery to synthesize 5-HT is not present in these
glutamate-containing neurons, it is suggested that thalamocortical
afferents "borrow" 5-HT via transporter uptake and release it
during the several postnatal weeks in which SERT is expressed (Lebrand
et al., 1996 ).
Thus, factors that regulate SERT expression on these thalamocortical
afferents would play a significant role in cortical development. SERT
expression can be regulated by several different triggers, including
receptor stimulation (Launay et al., 1994 ; Miller and Hoffman, 1994 )
and kinase activity (Jayanthi et al., 1994 ; Yura et al., 1996 ). The
activation of protein kinase C directly phosphorylates SERT
(Ramamoorthy et al., 1998 ), and this activation correlates with an
internalization of the transporter (Qian et al., 1997 ). SERTs are the
site of action of a number of psychostimulants that are transporter
substrates (amphetamine) or antagonists (cocaine, fluoxetine). In
heterologous expression systems, these drugs regulate surface SERT
expression (Ramamoorthy and Blakely, 1999 ). In the present experiments,
we test the hypothesis that SERT agonists and antagonists
differentially regulate the expression of endogenous SERT on
glutamatergic, thalamocortical neurons during development.
 |
MATERIALS AND METHODS |
Chemicals and reagents. All general cell culture
reagents were obtained from Life Technologies (Gaithersburg,
MD). Papain was obtained from Worthington (Freehold, NJ).
Radiolabeled compounds and immunoblot detection reagents were obtained
from Amersham Pharmacia Biotech (Arlington Heights, IL). All antibodies
were obtained from Chemicon (Temecula, CA). Biotinylation reagents were
obtained from Pierce (Rockford, IL). Vectashield was obtained from
Vector Laboratories (Burlingame, CA). All other drugs and reagents were
obtained from Sigma.
Cell culture and uptake assays. Primary cultures of
thalamocortical neurons were prepared from Sprague Dawley rat embryos at age embryonic day 18 (E18). The thalamus was dissected and then
minced in HEPES-buffered HBSS without calcium and magnesium. Tissue was digested in papain solution (Earle's balanced salt solution, pH 7.3, 20 U/ml papain, 1 mM
L-cysteine, 0.5 mM EDTA, and 0.1 U/ml DNase I). Tissue was incubated for 20 min at 37°C followed by gentle trituration, dilution, and plating. To obtain pure
neuronal cultures, mixed cultures were treated for 48 hr with 10 µM cytosine arabinoside; treatment was
initiated 24 hr after plating. Cells were maintained in Earle's MEM
supplemented with 10% FBS. Drugs and medium were added from the time
of plating and replaced every 6 hr for the duration of the experiment;
in experiments not requiring drug application, medium was changed every
24 hr. Uptake assays were performed as described previously (Bernstein
and Quick, 1999 ). The final [3H]5-HT
concentration of the assay solution was 40 nM;
the total 5-HT concentration of the assay solution was 30 µM. To minimize changes in transporter
expression during the assay, assay times were 10 min. Before assay,
cells were washed five times with 2 ml of HBSS to minimize residual
effects of chronic drug treatments on 5-HT uptake. This protocol was
chosen because it yielded statistically equivalent uptake results in
untreated cultures and cultures treated for 24 hr with 300 µM cocaine (data not shown). Statistical
analyses of the uptake data were performed using SPSS (Chicago, IL).
Immunocytochemistry and confocal microscopy. For
immunostaining experiments, neurons were plated on glass coverslips
pretreated with poly-L-lysine (10 µg/ml) and
fixed with 4% paraformaldehyde. After three washes with PBS,
cells were permeabilized for 10 min in PBS containing 0.1% Triton
X-100 incubated for 1 hr in blocking solution (PBS, 1% bovine serum
albumin, and 5% goat serum). Neurons were incubated with primary
antibodies (anti-SERT, 1:2000; anti-glutamate, 1:1000) for 1 hr at room
temperature followed by 30 min incubation with secondary antibodies
(FITC-conjugated IgG; Texas Red-conjugated IgG). Cells were then washed
five times in blocking solution, and the coverslips were mounted on
glass slides using Vectashield. Fluorescent images were generated using
a Zeiss confocal microscope at 498 nm for FITC and 585 nm for Texas Red.
Biotinylation and immunoblotting. Biotinylation experiments
were performed as described previously (Qian et al., 1997 ; Davis et
al., 1998 ). The supernatant fractions (300 µl) were incubated with an
equal volume of Immunopure Immobilized Monomeric Avidin beads at room
temperature for 60 min. The beads were washed three times with
RIPA buffer, and adsorbed proteins were eluted with SDS sample
buffer (62.5 mM Tris-Cl, pH 6.8, 2% SDS, 100 mM -mercaptoethanol) at room temperature for
30 min. Samples were run on a 6% acrylamide gel and blotted onto
nitrocellulose membrane. For biotinylation experiments, analysis was
performed on aliquots (1) taken before incubation with beads (total
cell lysate), (2) of the supernatant fraction after adsorption and
centrifugation (intracellular fraction), and (3) of the bead eluate
(biotinylated fraction). Western blotting was performed as described
previously (Corey et al., 1994 ) using anti-SERT antibodies (1:500);
secondary antibodies were conjugated with HRP, and immunoreactive bands
were detected with enhanced chemiluminescence. To ensure equal amounts
of protein were being assayed in each condition, SERT levels were
quantified relative to actin levels in the same experiment.
Immunoreactive bands were scanned and quantified with ImageQuant
(Molecular Dynamics, Sunnyvale, CA).
 |
RESULTS |
To verify that SERT was expressed in developing thalamocortical
neurons in culture, dissociated thalamic neurons from E18 rats were
plated and examined at postnatal day 3 (P3) using confocal immunofluorescence microscopy (Fig.
1A). At P3, >90% of
the neurons that were immunoreactive for glutamate were also
immunoreactive for SERT. SERT antibody preabsorbed with a C-terminal
SERT peptide blocked all SERT immunoreactivity in these cells (data not
shown). To examine the time course of SERT expression during early
postnatal development in these neurons, we performed immunoblot
experiments on thalamic neurons cultured at E18 and compared the amount
of SERT immunoreactivity at six different early postnatal ages (Fig. 1B). SERT protein levels increased to a peak at P3
and declined thereafter; SERT immunoreactivity was measurable at P8 but
absent by P10. These results differed markedly from measurements of
actin immunoreactivity, which remained relatively constant over this same time period. Single experiments conducted on neurons cultured until P21, P28, or P33 failed to show any SERT immunoreactivity (data
not shown). These data in culture are very similar to previous results
performed in brain using radiolabeled citalopram binding, 5-HT
immunocytochemistry, and mRNA quantification (D'Amato et al., 1987 ;
Dori et al., 1996 ; Lebrand et al., 1998 ).

View larger version (26K):
[in this window]
[in a new window]
|
Figure 1.
SERT is expressed in thalamocortical neurons
during development. A, SERT colocalizes with glutamate.
P3 neurons were stained with an anti-glutamate antibody conjugated to
Texas Red and a C-terminal anti-SERT antibody conjugated to FITC.
B, SERT expression is transient. Total cellular SERT
protein levels were quantified with respect to maximal SERT expression
(P3). Data are from five separate experiments. The inset
shows a representative immunoblot from one experiment. Densitometry
measurements of SERT expression (top blot) were adjusted
relative to actin immunoreactivity (bottom blot)
measured in the same experiment.
|
|
Because SERT expression is one component necessary for thalamocortical
neurons to release 5-HT (Lebrand et al., 1996 ), regulation of SERT
expression should have a significant effect on 5-HT regulation of
cortical development. The high expression of SERT in thalamocortical cells in culture allowed us to examine endogenous SERT regulation in
neurons. Because SERT can be regulated in expression systems by
agonists and antagonists (Ramamoorthy and Blakely, 1999 ), we examined the role of such molecules on SERT expression in
thalamocortical neurons. E18-plated cultures were chronically treated
with 10 µM 5-HT, and protein levels were assessed at
subsequent time points by total cell SERT immunoreactivity (Fig.
2A). Compared with
untreated control cultures, 5-HT-treated cultures showed two
differences: (1) total SERT protein levels were approximately fourfold
higher, and (2) both the peak of SERT expression and the loss of SERT immunoreactivity were shifted to older ages by several days. The increase in total SERT protein levels was 5-HT concentration-dependent (Fig. 2B), with half-maximal increases in total SERT
protein levels assessed at P3 occurring at ~1
µM. This is near the apparent affinity of SERT
for 5-HT transport (Blakely et al., 1991 ; Hoffman et al., 1991 ).

View larger version (36K):
[in this window]
[in a new window]
|
Figure 2.
SERT agonists and antagonists differentially
regulate the time course of SERT expression. A, 5-HT
regulates total SERT proteins levels. Cultures were treated from time
of plating with 10 µM 5-HT. Total cellular SERT protein
levels for untreated and 5-HT-treated cultures were quantified relative
to maximal SERT expression (5-HT-treated neurons at P5). Data are from
four separate experiments. The inset shows
representative SERT immunoreactivity from one experiment.
B, 5-HT regulation of total SERT protein levels is
concentration-dependent. Cultures were treated with different
concentrations of 5-HT and assayed at P3. Data are from three separate
experiments and plotted relative to untreated cultures.
C, SERT agonists and antagonists have differential
effects on total SERT protein levels. Cultures were treated with the
following drug concentrations (in µM): 10 5-HT, 10 MDMA,
300 cocaine, and 300 fluoxetine. Total cellular SERT protein levels
quantified relative to SERT expression of 5-HT-treated cultures at P5.
Data are from four separate experiments. Average SEs across all ages
for each treatment group are summarized by the error bars plotted at
P3. D, Time course of 5-HT effects on total SERT protein
levels. Cultures were treated with 10 µM 5-HT for four
different lengths of time from the time of plating. Data are from three
separate experiments. Average SEs across all ages for each treatment
group are summarized by the error bars plotted at P5.
|
|
SERT is the site of action for drugs of abuse such as
3,4-methylenedioxymethamphetamine (MDMA) and cocaine, and for
therapeutic drugs such as fluoxetine. E18-plated cultures were
chronically treated with these compounds, and protein levels were
assessed at subsequent time points by examining total cell SERT
immunoreactivity (Fig. 2C). MDMA, a SERT substrate (Rudnick
and Wall, 1992 ), regulated SERT expression similarly to 5-HT.
Cotreatment of cultures with 5-HT and either of the SERT antagonists
cocaine or fluoxetine eliminated both the fourfold increase in peak
SERT expression and the increase in expression time course mediated by
5-HT. The time course of SERT immunoreactivity in the presence of
cocaine and fluoxetine was decreased compared with untreated controls (compare with Fig. 2A). This could be caused by
specific action of these compounds on SERT expression; however, it may
also indicate that in untreated cultures there is some uptake of 5-HT
from nominally 5-HT-free culture media. The continued presence of 5-HT
was required to maintain the increased time course of SERT expression
(Fig. 2D): removal of substrate at a given age
resulted in a noticeable decline in SERT expression soon thereafter. In
summary, these data suggest that the effect of 5-HT on SERT protein
expression is mediated through actions on SERT, that SERT agonists
increase and SERT antagonists decrease the magnitude and time course of SERT protein expression respectively, and that the continued presence of substrate is necessary for maintaining the increase in SERT expression.
The ability of thalamocortical neurons to use 5-HT as a "borrowed"
transmitter requires the expression of functional SERTs. To examine
functional SERT expression, we performed
[3H]5-HT uptake assays on cultures
chronically treated with MDMA alone or MDMA in the presence of cocaine
(Fig. 3A). Assays were performed in the presence of 5-HT alone. Qualitatively, 5-HT uptake at
different ages resembled that for total SERT protein levels. That is,
MDMA-treated cultures showed 5-HT uptake that was increased in both
magnitude and time course compared with cultures treated with MDMA and
cocaine. However, although the time course of 5-HT uptake and SERT
immunoreactivity were comparable, at all ages the magnitude of 5-HT
uptake was greater than that predicted from the changes seen in protein
levels (Fig. 3B). For example, at P3, the ratio of
immunoreactivity in MDMA-treated cultures to that of MDMA plus
cocaine-treated cultures was ~3. For 5-HT uptake, this ratio was >7.
These data suggested that MDMA was not only affecting total SERT
protein levels but the fraction of SERT that was functional.

View larger version (43K):
[in this window]
[in a new window]
|
Figure 3.
MDMA regulates the subcellular distribution
of SERT. A, MDMA upregulates SERT function. Cultures
were treated from time of plating with 10 µM MDMA or 10 µM MDMA plus 300 µM cocaine. Uptake data
are from three separate experiments, three wells per data point per
experiment. B, 5-HT uptake is upregulated by MDMA to a
greater extent than total protein levels. At each age, uptake and total
cellular protein levels were determined from the same cultures and
plotted as the ratio of values obtained for MDMA-treated versus MDMA
plus cocaine-treated cultures. Data are from two separate experiments.
C, MDMA causes a subcellular redistribution of SERT
protein. Surface biotinylation experiments were performed on cultures
from two different ages (P0, P5) treated from time of plating with 10 µM MDMA (M) or 10 µM MDMA plus 300 µM cocaine
(M + C). Representative immunoblots
examining SERT and Na/K ATPase immunoreactivity are shown.
D, Quantification of SERT expression from experiments as
performed in C. The amount of biotinylated (surface) and
nonbiotinylated (intracellular) SERT is plotted as percent of total
SERT. Data are from three separate experiments. Dashed
lines indicate the average amount of surface SERT in the
presence of MDMA and in the presence of MDMA plus cocaine.
Asterisks indicate significant differences between
treatment groups (p < 0.05).
E, Time course of agonist-induced subcellular
redistribution of SERT. Untreated cultures at P3 were acutely treated
with 10 µM MDMA or 10 µM MDMA plus 300 µM cocaine for the time indicated on the abscissa;
cultures were then subjected to surface biotinylation. Data are from
two separate experiments. Asterisks indicate significant
differences between treatment groups at particular time points
(p < 0.05). F, The
subcellular redistribution of SERT by MDMA is prevented by pretreatment
with PKC activators. Cultures were treated from time of plating with 10 µM MDMA in the presence of 1 µM PMA or
4 PDD and assayed by biotinylation at P0. Data are from three
separate experiments. Asterisk indicates significant
differences between treatment groups (p < 0.05).
|
|
Neurotransmitter transporters can be regulated not only by altering
rates of flux through the transporter (Deken et al., 2000 ), but also by
altering the subcellular distribution of transporter protein between
intracellular sites and the plasma membrane (for review, see Beckman
and Quick, 1998 ). This is true for SERT (Qian et al., 1997 ; Ramamoorthy
and Blakely, 1999 ). The relative increase in 5-HT uptake compared with
SERT protein levels was consistent with the hypothesis that, in the
presence of MDMA, a greater proportion of SERT is localized to the
plasma membrane. To test this hypothesis, we performed surface
biotinylation experiments and examined the subcellular distribution of
SERT (Fig. 3C). Cultures were treated with MDMA alone or
MDMA in the presence of cocaine, and examined at P0 or P5. At both
ages, and in each treatment condition, the majority of SERT was found
intracellularly. However, in cocaine-treated cultures, ~20% of SERT
was surface biotinylated; in MDMA-treated cultures, the amount of SERT
found in the biotinylated fraction increased to ~40% (Fig.
3D). These drugs had no effects on the subcellular
distribution of the Na/K ATPase (Fig. 3C). The approximate twofold increase in surface SERT expression would account for the
increase in uptake compared with total protein levels (Fig. 3B). These data suggest that MDMA has two effects on
regulating SERT: it increases total SERT protein levels and it
increases the relative amount of SERT on the plasma membrane.
The effect of SERT substrates on upregulation of total protein levels
appeared to require prolonged drug treatment (Fig.
2D). To determine whether the substrate-mediated
effects on SERT redistribution occurred on a similar time scale, we
acutely applied MDMA alone or in combination with cocaine to previously
untreated P3 cultures (Fig. 3E). The MDMA-induced
subcellular redistribution of SERT occurred within minutes. This time
course is similar to results seen with substrate-mediated
redistribution of GABA transporters (Bernstein and Quick, 1999 ).
Another feature of many neurotransmitter transporters is its
internalization in the presence of activators of protein kinase C (PKC)
(Beckman and Quick, 1998 ). In expression systems, SERT substrates
prevent PKC phosphorylation of SERT and increase the relative amount of
surface SERT expression (Ramamoorthy and Blakely, 1999 ). To determine
whether a similar mechanism was occurring in neurons, MDMA-treated
cultures were also treated with either the phorbol ester PMA or an
inactive control (4 PDD). We reasoned that the addition of PMA would
increase the likelihood that SERT would be PKC phosphorylated. The
addition of PMA prevented the MDMA-mediated redistribution of SERT to
the plasma membrane, as assessed by surface biotinylation (Fig.
3F).
 |
DISCUSSION |
Neonatal serotonin (5-HT) depletion results in changes in neuronal
morphology (Bennett-Clarke et al., 1994 ) and decreased synaptic density
(Mazer et al., 1997 ). Conversely, 5-HT during early postnatal
development modulates synaptic plasticity (Kojic et al., 1997 ; Edagawa
et al., 2001 ), activity (Rhoades et al., 1994 ), and maturation (Borella
et al., 1997 ). In rats, experimental alterations in 5-HT levels during
the early postnatal period also results in characteristic behavioral
syndromes (Breese et al., 1978 ; Tricklebank, 1985 ) and long-term
cognitive impairments (Nyakas et al., 1994 ; Buwalda et al., 1995 ;
Whitaker-Azmitia et al., 1995 ). In addition, disruption of normal
serotonergic signaling via gene knock-out of monoamine oxidase, 5-HT1B
receptors, or 5-HT transporters (SERTs) reveals that 5-HT systems play
a crucial role in the formation and segregation of somatosensory (Blue
et al., 1991 ; Cases et al., 1996 ) and visual system sensory maps (Upton
et al., 1999 ; Salichon et al., 2001 ). A significant serotonergic input
to cortex during development comes from thalamocortical neurons that
borrow 5-HT (Lebrand et al., 1996 ; Bruning and Liangos, 1997 ). The
borrowing of 5-HT during early postnatal development is attributable to the transient expression of SERT and the vesicular amine transporter (Lebrand et al., 1998 ). In the present experiments, we show that 5-HT
and psychostimulants regulate the time course and peak expression of
SERT in thalamocortical neurons. These data suggest that some of the
actions of psychostimulants in neocortical development may be
attributable to alterations in SERT expression and concomitant changes
in 5-HT signaling.
The ability of endogenous SERT to be differentially regulated by
psychostimulants that act as either antagonists or substrates of SERT
is consistent with evidence from heterologous expression systems
(Ramamoorthy and Blakely, 1999 ). This regulation occurs via three
mechanisms: a change in the total amount of SERT protein, a change in
the time course of SERT expression, and a redistribution of SERT
between intracellular stores and the plasma membrane. Yet to be
determined are the molecular processes that underlie these mechanisms.
The substrate-induced upregulation of total protein expression levels
would indicate regulation of protein synthesis. Substrates are clearly
not the only signal for controlling SERT protein levels because SERT
disappears from these neurons even in the presence of substrate. The
regulation of SERT expression time course appears to require the
sustained presence of substrate because removal of substrate results in
a more rapid rate of disappearance of cellular SERT protein. The much
more rapid substrate-induced increase of SERT to the plasma membrane
suggests a mechanism by which rates of SERT internalization or
externalization are altered.
Although regulation of transporter expression is a common feature of
plasma membrane transporters, the details of how agonists and
antagonists affect transporter function appear to be
transporter-specific. Similarly to SERT, heterologously expressed
norepinephrine transporters (NETs) are downregulated after chronic
treatment with the NET antagonist desipramine, perhaps through changes
in protein expression and/or transporter turnover (Zhu et al., 1998 ).
In contrast to SERT, the NET agonists norepinephrine and amphetamine
also cause decreases in expression (Zhu et al., 2000 ). In
heterologously expressed dopamine transporters (DATs), DAT agonists
dopamine and amphetamine cause an net accumulation of DAT
intracellularly; this internalization is blocked by the DAT antagonist
cocaine (Saunders et al., 2000 ). In endogenously expressed GABA
transporters, agonists cause a net externalization of the transporter,
and antagonists cause a net internalization; however, there is no
effect on total transporter protein levels (Bernstein and Quick, 1999 ).
The mechanisms and biological relevance underlying these different
effects of transporter substrates and antagonists on transporter
expression is not known. However, the ability of amine transporters to
be differentially regulated by psychostimulants is important both in
understanding the molecular basis of drug abuse and in the design of
strategies to intervene in the abuse process.
 |
FOOTNOTES |
Received July 9, 2001; revised Sept. 25, 2001; accepted Oct. 3, 2001.
This work was supported by National Institutes of Health Grants HD38760
and DA10509 and by a National Alliance for Research on Schizophrenia
and Depression Young Investigator Award to M.W.Q.
Correspondence should be addressed to Michael W. Quick, Department of
Neurobiology, CIRC 446, University of Alabama at Birmingham, 1719 Sixth Avenue South, Birmingham, AL 35294-0021. E-mail:
quick{at}nrc.uab.edu.
This article is published in
The Journal of Neuroscience, Rapid Communications Section,
which publishes brief, peer-reviewed papers online, not in print. Rapid
Communications are posted online approximately one month earlier than
they would appear if printed. They are listed in the Table of Contents
of the next open issue of JNeurosci. Cite this article as:
JNeurosci, 2001, 21:RC192 (1-6). The
publication date is the date of posting online at
www.jneurosci.org.
 |
REFERENCES |
-
Beckman ML,
Quick MW
(1998)
Neurotransmitter transporters: regulators of function and functional regulation.
J Membr Biol
164:1-10.
-
Bennett-Clarke CA,
Leslie MJ,
Chiaia NL,
Rhoades RW
(1993)
Serotonin 1B receptors in the developing somatosensory and visual cortices are located on thalamocortical axons.
Proc Natl Acad Sci USA
90:153-157.
-
Bennett-Clarke CA,
Leslie MJ,
Lane RD,
Rhodes RW
(1994)
Effect of serotonin depletion on vibrissa-related patterns of thalamic afferents in the rat's somatosensory cortex.
J Neurosci
14:7594-7607.
-
Bernstein EM,
Quick MW
(1999)
Regulation of
-aminobutyric acid (GABA) transporters by extracellular GABA.
J Biol Chem
274:889-895. -
Blakely RD,
Berson HE,
Fremeau RT,
Caron MG,
Peek MM,
Prince HK,
Bradley CC
(1991)
Cloning and expression of a functional serotonin transporter from rat brain.
Nature
354:66-70.
-
Blue ME,
Erzurumlu RS,
Jhaveri S
(1991)
A comparison of pattern formation by thalamocortical and serotonergic afferents in the rat barrel field cortex.
Cereb Cortex
1:380-389.
-
Borella A,
Bindra M,
Whitaker-Azmitia PM
(1997)
Role of the 5-HT1A receptor in development of the neonatal rat brain: preliminary behavioral studies.
Neuropharmacology
36:445-450.
-
Breese GR,
Vogel RA,
Mueller RA
(1978)
Biochemical and behavioral alterations in developing rats treated with 5,7-dihydroxytryptamine.
J Pharmacol Exp Ther
205:587-595.
-
Bruning G,
Liangos O
(1997)
Transient expression of the serotonin transporter in the developing mouse thalamocortical system.
Acta Histochem
99:117-121.
-
Buwalda B,
Nyakas C,
Vosselman HJ,
Luitem PGM
(1995)
Effects of early postnatal anoxia on adult learning and emotion in rats.
Behav Brain Res
67:85-90.
-
Buznikov GA,
Shmukler YB
(1981)
Possible role of "prenervous" neurotransmitters in cellular interactions of early embryogenesis: a hypothesis.
Neurochem Res
6:55-68.
-
Cases O,
Vitalis T,
Seif I,
De Maeyer E,
Sotelo C,
Gaspar P
(1996)
Lack of barrels in the somatosensory cortex of monoamine oxidase A-deficient mice: role of serotonin excess during the critical period.
Neuron
16:297-307.
-
Corey JL,
Davidson N,
Lester HA,
Brecha N,
Quick MW
(1994)
Protein kinase C modulates the activity of cloned
-aminobutyric acid transporter expressed in Xenopus oocytes via regulated subcellular redistribution of the transporter.
J Biol Chem
269:14759-14767. -
D'Amato RJ,
Blue ME,
Largent BL,
Lynch DR,
Ledbetter DJ,
Molliver ME,
Snyder SH
(1987)
Ontogeny of the serotonergic projection to rat neocortex: transient expression of a dense innervation to primary sensory areas.
Proc Natl Acad Sci USA
84:4322-4326.
-
Davis KE,
Straff DJ,
Weinstein EA,
Bannerman PG,
Correale DM,
Rothstein JD,
Robinson MB
(1998)
Multiple signaling pathways regulate cell surface expression and activity of the excitatory amino acid carrier 1 subtype of glu transporter in C6 glioma.
J Neurosci
18:2475-2585.
-
Deken S,
Beckman M,
Boos L,
Quick MW
(2000)
Permeation through GABA transporters is regulated by syntaxin 1A.
Nat Neurosci
3:998-1003.
-
Dori I,
Dinopoulos A,
Blue ME,
Parnavelas JG
(1996)
Regional differences in the ontogeny of the serotonergic projection to the cerebral cortex.
Exp Neurol
138:1-15.
-
Edagawa Y,
Saito H,
Abe K
(2001)
Endogenous serotonin contributes to a developmental decrease in long-term potentiation in the rat visual cortex.
J Neurosci
21:1532-1537.
-
Hansson SR,
Mezey E,
Hoffman BJ
(1998)
Serotonin transporter messenger RNA in the developing rat brain: early expression in serotonergic neurons and transient expression in non-serotonergic neurons.
Neuroscience
83:1185-1201.
-
Hoffman BJ,
Mezey E,
Brownstein MJ
(1991)
Cloning of a serotonin transporter affected by antidepressants.
Science
254:579-580.
-
Jayanthi LD,
Ramamoorthy S,
Mahesh VB,
Leibach FH,
Ganapathy V
(1994)
Calmodulin-dependent regulation of the catalytic function of the human serotonin transporter in placental choriocarcinoma cells.
J Biol Chem
269:14424-14429.
-
Kojic L,
Gu Q,
Douglas RM,
Cynader MS
(1997)
Serotonin facilitates synaptic plasticity in kitten visual cortex: an in vitro study.
Brain Res Dev Brain Res
101:299-304.
-
Lauder JM
(1993)
Neurotransmitters as growth regulatory signals: role of receptors and second messengers.
Trends Neurosci
16:233-239.
-
Launay JM,
Bondoux D,
Oset-Gasque MJ,
Emami S,
Mutel V,
Haimart M,
Gespach C
(1994)
Increase of human platelet serotonin uptake by atypical histamine receptors.
Am J Physiol
266:R526-R536.
-
Lebrand C,
Cases O,
Aldebrecht C,
Doye A,
Alvarez C,
El-Mestikawy S,
Seif I,
Gaspar P
(1996)
Transient uptake and storage of serotonin in developing thalamic neurons.
Neuron
17:823-835.
-
Lebrand C,
Cases O,
Wehrle R,
Blakely RD,
Edwards RH,
Gaspar P
(1998)
Transient developmental expression of monoamine transporters in the rodent forebrain.
J Comp Neurol
401:506-524.
-
Mazer C,
Muneyyirci J,
Taheny K,
Raio N,
Borella A,
Whitaker-Azmitia P
(1997)
Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits.
Brain Res
760:68-73.
-
Miller KJ,
Hoffman BJ
(1994)
Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP.
J Biol Chem
269:27351-27356.
-
Nyakas C,
Nuwalda B,
Kramers RKJ,
Traber J,
Luiten PGM
(1994)
Postnatal development of hippocampal and neocortical cholinergic and serotonergic innervation in rat: effects of nitrite-induced prenatal hypoxia and nimodipine treatment.
Neuroscience
39:541-559.
-
Qian Y,
Galli A,
Ramamoorthy S,
Risso S,
DeFelice LJ,
Blakely RD
(1997)
Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression.
J Neurosci
17:45-57.
-
Ramamoorthy S,
Blakely RD
(1999)
Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants.
Science
285:763-766.
-
Ramamoorthy S,
Giovanetti E,
Qian Y,
Blakely RD
(1998)
Phosphorylation and regulation of antidepressant-sensitive serotonin transporters.
J Biol Chem
273:2458-2466.
-
Rhoades RW,
Bennett-Clarke CA,
Shi M-Y,
Mooney RD
(1994)
Effects of 5-HT on thalamocortical synaptic transmission in the developing rat.
J Neurophysiol
72:2438-2450.
-
Rudnick G,
Wall SC
(1992)
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.
Proc Natl Acad Sci USA
89:1817-1821.
-
Salichon N,
Gaspar P,
Upton AL,
Picaud S,
Hanoun N,
Hamon M,
De Maeyer E,
Murphy DL,
Mossner R,
Lesch KP,
Hen R,
Seif I
(2001)
Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase A and 5-HT transporter knock-out mice.
J Neurosci
21:884-896.
-
Saunders C,
Ferrer JV,
Shi L,
Chen J,
Merrill G,
Lamb ME,
Leeb-Lundberg LM,
Carvelli L,
Javitch JA,
Galli A
(2000)
Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.
Proc Natl Acad Sci USA
97:6850-6855.
-
Tricklebank MD
(1985)
The behavioral response to 5-HT receptor agonists and subtypes of the central 5-HT receptor.
Trends Pharmacol Sci
3:403-406.
-
Upton AL,
Salichon N,
Lebrand C,
Ravary A,
Blakely R,
Seif I,
Gaspar P
(1999)
Excess of serotonin (5-HT) alters the segregation of ipsilateral and contralateral retinal projections in monoamine oxidase A knock-out mice: possible role of 5-HT uptake in retinal ganglion cells during development.
J Neurosci
19:7007-7024.
-
Whitaker-Azmitia PM,
Borella A,
Raio N
(1995)
Serotonin depletion in the adult rat causes loss of dendritic marker MAP-2. A new animal model of schizophrenia?
Neuropharmacology
12:269-272.
-
Yura A,
Kiuchi Y,
Uchikawa T,
Uchida J,
Yamazaki K,
Oguchi K
(1996)
Possible involvement of calmodulin-dependent kinases in Ca2+-dependent enhancement of [3H]5-hydroxytryptamine uptake in rat cortex.
Brain Res
738:96-102.
-
Zhu MY,
Blakely RD,
Apparsundaram S,
Ordway GA
(1998)
Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine.
J Neurochem
70:1547-1555.
-
Zhu MY,
Shamburger S,
Li J,
Ordway GA
(2000)
Regulation of the human norepinephrine transporter by cocaine and amphetamine.
J Pharmacol Exp Ther
295:951-959.
Copyright © Society for Neuroscience 0270-6474//$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
L. D. Jayanthi, D. J. Samuvel, R. D. Blakely, and S. Ramamoorthy
Evidence for Biphasic Effects of Protein Kinase C on Serotonin Transporter Function, Endocytosis, and Phosphorylation
Mol. Pharmacol.,
June 1, 2005;
67(6):
2077 - 2087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Seidel, E. A. Singer, H. Just, H. Farhan, P. Scholze, O. Kudlacek, M. Holy, K. Koppatz, P. Krivanek, M. Freissmuth, et al.
Amphetamines Take Two to Tango: an Oligomer-Based Counter-Transport Model of Neurotransmitter Transport Explores the Amphetamine Action
Mol. Pharmacol.,
January 1, 2005;
67(1):
140 - 151.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|